Larry Ramer has conducted research and written articles on U.S. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines. He may purchase shares of Eisai during the week of April 10. ![]() As evidence of the latter point, NVAX stock jumped from $7.34 as of the close of trading on April 4 to $8.46 as of the market close on April 6.Īs of the date of publication, Larry Ramer owned shares of NVAX. Moreover, Jacobs’ experience should be an asset for Novavax and NVAX stock going forward.Īlso positive for the shares are its high short interest (nearly 40% of NVAX stock was being sold short as of April 6) and the fact that the Street seems to have viewed the data the company released on April 5 positively. In any event, the fact that Jacobs would choose to become CEO of Novavax after his successful tenure at Harmony suggests that Novavax’s prospects are strong. While a short seller has recently alleged that Harmony covered up the deaths of 12 patients who were taking the drug during clinical trials of the treatments, investment bank Raymond James, as well as Harmony itself, have denied the charges, with the bank writing that “Wakix’s safety profile is not an issue based on our own diligence with prescribers.” Moreover, Goldman Sachs recently named Harmony one of the stocks it believes are best positioned to avoid a recession. During his tenure, Harmony launched a successful IPO in 2020, and its stock price climbed from $35 when it started trading to $53 just before it was announced that Jacobs was leaving.Īlso, during his stint as CEO, the FDA approved the company’s narcolepsy treatment, Wakix. Specifically, he was CEO of Harmony Biosciences (NASDAQ: HRMY ) from 2018 until the beginning of 2023. Speaking of the company’s new CEO, Jacobs, as I wrote earlier, has an excellent resume. Three Other Reasons to Be Bullish on NVAX Stock Still, with the firm under the leadership of a new, highly accomplished CEO, John Jacobs, I think it may indeed be able to do what’s necessary on the marketing front to at least come close to meeting my projections. That’s nearly 12 times its current market capitalization of $729 million.īut to make this forecast a reality, the company has to greatly step up its marketing efforts, both to doctors and consumers. If the drug maker meets these forecasts and gets a price-sales ratio of just two, its market capitalization would be $8.7 billion. Let’s say the market grows to $4.5 billion next year, and Novavax gets 10% of that revenue. Meanwhile, revenue from flu vaccines came in at $4.28 billion in 2022. Let’s say that Novavax gets 15% of that revenue. Why NVAX Stock Can Soar Almost 12 TimesĪccording to Statista, global revenue from the coronavirus vaccine is expected to reach $26 billion next year. Moreover, the combination shot was as safe as taking Novavax’s flu shot and coronavirus jab separately. Regarding Novavax’s combined flu-Covid vaccine, the company reported that the job had elicited effective responses against both the coronavirus and “and multiple influenza strains.,” said. Remember that if the entire population had received three booster shots each, 300 booster shots per 100 people would be administered. In the U.K., that figure is 60, in France, it’s 71, and in Germany, it’s 78. For example, in the U.S., as of last month, only 34 boosters had been administered per 100 people. ![]() ![]() Meanwhile, data indicate that high percentages of the populations of other developed countries have yet to receive boosters. The fact that one dose of Novavax’s vaccine generated a “comparable” response to three shots of the mRNA vaccines should lead some doctors to recommend that their patients get Novavax’s vaccine instead of the mRNA jabs. ![]() InvestorPlace - Stock Market News, Stock Advice & Trading Tips Strong Clinical Data Gives Novavax a Huge Opportunityĭata unveiled by Novavax on April 5 showed that a single booster dose of its Covid-19 shot generated “immune responses were comparable to three total doses of the approved messenger RNA (mRNA) vaccines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |